Larimar Therapeutics Inc
LRMR3.255USD
-0.185-5.38%
交易中 （美东）报价延迟15分钟
208.41M总市值
亏损市盈率 TTM
关于 Larimar Therapeutics Inc 公司
Larimar Therapeutics, Inc. 是一家临床阶段的生物技术公司。该公司专注于利用其新型细胞穿透肽 (CPP) 技术平台为患有复杂罕见疾病的患者开发治疗方法。该公司的主要候选产品 nomlabofusp 是一种皮下注射的重组融合蛋白，旨在将一种必需蛋白组织 frataxin (FXN) 输送到弗里德赖希共济失调 (FA) 患者的线粒体。FA 是一种罕见、渐进且致命的疾病，患者由于基因异常无法产生足够的 FXN。其 CPP 平台使治疗分子能够穿过细胞膜以达到细胞内靶点，有可能治疗其他罕见病和孤儿病。该公司打算利用其专有平台针对以细胞内内容或活动缺陷或改变为特征的其他孤儿适应症。
公司简介
公司代码LRMR
公司名称Larimar Therapeutics Inc
上市日期Jun 19, 2014
CEODr. Carole S. Ben-Maimon, M.D.
员工数量65
证券类型Ordinary Share
年结日Jun 19
公司地址Three Bala Plaza East. Suite 506
城市BALA CYNWYD
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编19004
电话18445119056
网址https://larimartx.com/
公司代码LRMR
上市日期Jun 19, 2014
CEODr. Carole S. Ben-Maimon, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas Edward Hamilton
Mr. Thomas Edward Hamilton
Independent Director
Independent Director
590.81K
-18.42%
Dr. Carole S. Ben-Maimon, M.D.
Dr. Carole S. Ben-Maimon, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.86K
-11.38%
Mr. Michael (Mike) Celano
Mr. Michael (Mike) Celano
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
82.56K
-8.20%
Dr. Russell G. (Rusty) Clayton, Sr.
Dr. Russell G. (Rusty) Clayton, Sr.
Chief Medical Officer
Chief Medical Officer
45.81K
+103.58%
Dr. Gopi Shankar, Ph.D.
Dr. Gopi Shankar, Ph.D.
Chief Development Officer
Chief Development Officer
10.63K
-62.46%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Director
Independent Director
2.00K
--
Mr. Joseph (Joe) Truitt
Mr. Joseph (Joe) Truitt
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Thomas Edward Hamilton
Mr. Thomas Edward Hamilton
Independent Director
Independent Director
590.81K
-18.42%
Dr. Carole S. Ben-Maimon, M.D.
Dr. Carole S. Ben-Maimon, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.86K
-11.38%
Mr. Michael (Mike) Celano
Mr. Michael (Mike) Celano
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
82.56K
-8.20%
Dr. Russell G. (Rusty) Clayton, Sr.
Dr. Russell G. (Rusty) Clayton, Sr.
Chief Medical Officer
Chief Medical Officer
45.81K
+103.58%
Dr. Gopi Shankar, Ph.D.
Dr. Gopi Shankar, Ph.D.
Chief Development Officer
Chief Development Officer
10.63K
-62.46%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Director
Independent Director
2.00K
--
收入明细
FY2019
暂无数据
地区USD
名称
营收
占比
United States (Country)
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Deerfield Management Company, L.P.
35.76%
RA Capital Management, LP
7.06%
Janus Henderson Investors
6.51%
Blue Owl Capital Holdings LP
5.58%
Opaleye Management Inc.
4.62%
Other
40.47%
持股股东
持股股东
占比
Deerfield Management Company, L.P.
35.76%
RA Capital Management, LP
7.06%
Janus Henderson Investors
6.51%
Blue Owl Capital Holdings LP
5.58%
Opaleye Management Inc.
4.62%
Other
40.47%
股东类型
持股股东
占比
Hedge Fund
56.00%
Investment Advisor
18.28%
Investment Advisor/Hedge Fund
14.21%
Venture Capital
9.44%
Research Firm
4.86%
Individual Investor
1.43%
Pension Fund
0.17%
Bank and Trust
0.06%
Private Equity
0.06%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
236
70.33M
109.85%
-3.04M
2025Q1
241
65.66M
102.55%
-8.64M
2024Q4
237
68.11M
106.77%
-7.20M
2024Q3
225
68.88M
107.96%
-7.04M
2024Q2
207
69.87M
109.52%
-2.95M
2024Q1
185
68.09M
106.93%
+8.87M
2023Q4
161
43.68M
97.08%
-3.08M
2023Q3
157
39.54M
87.67%
-8.23M
2023Q2
151
39.82M
92.04%
-2.98M
2023Q1
137
39.73M
94.04%
-4.68M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Deerfield Management Company, L.P.
21.23M
33.16%
--
--
Mar 31, 2025
RA Capital Management, LP
6.05M
9.44%
--
--
Mar 31, 2025
Janus Henderson Investors
5.57M
8.7%
-871.32K
-13.52%
Mar 31, 2025
Blue Owl Capital Holdings LP
4.78M
7.46%
+125.00K
+2.69%
Mar 31, 2025
Opaleye Management Inc.
3.95M
6.17%
+2.04M
+106.49%
Apr 09, 2025
Millennium Management LLC
3.56M
5.57%
+2.89M
+429.50%
Jun 12, 2025
BlackRock Institutional Trust Company, N.A.
2.84M
4.44%
-138.47K
-4.65%
Mar 31, 2025
Goldman Sachs & Company, Inc.
2.60M
4.06%
-1.46M
-35.91%
Mar 31, 2025
The Vanguard Group, Inc.
2.22M
3.46%
+24.88K
+1.13%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.44M
2.25%
+458.40K
+46.58%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
0.27%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 3000 ETF
0%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
查看更多
iShares Neuroscience and Healthcare ETF
占比0.27%
iShares Micro-Cap ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0.01%
iShares Russell 3000 ETF
占比0%
ALPS Medical Breakthroughs ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
May 28, 2020
Merger
12<1
May 28, 2020
Merger
12<1
May 28, 2020
Merger
12<1
May 28, 2020
Merger
12<1
公告日期
类型
比率
May 28, 2020
Merger
12<1
May 28, 2020
Merger
12<1
May 28, 2020
Merger
12<1
May 28, 2020
Merger
12<1
